Age (years) | 62 (10) | 64 (10) | 60(12) | 0.96 | 0.9 to 1.03 |
Range | 30–81 | 30–81 | 35–76 | 0.83 | 0.55 to 1.14 |
Male/female | 43/30 | 28/19 | 15/11 | | |
BSA (m2) | 1.88 (.19) | 1.88 (.2) | 1.88 (.18) | 0.8 | 0.01 to 4.3 |
Range | 1.37–2.26 | 1.37–2.22 | 1.56–2.26 | | |
NYHA II | 53 (73%) | 33 (70%) | 20 (76%) | 1.95 | 0.26 to 14.8 |
NYHA III | 20 (27%) | 14 (30%) | 6 (24%) | | |
EF (%) | 56 (14) | 56 (14) | 55 (13) | 0.97 | 0.91 to 1.03 |
Range | 18–86 | 18–81 | 30–86 | | |
LA (mm) | 48 (7) | 47 (6) | 49 (8) | 0.96 | 0.85 to 1.09 |
Range | 31–72 | 33–66 | 31–72 | | |
AF duration (months) | 15 (21) | 12 (14) | 25 (28) | 1.07 | 1.01 to 1.13** |
Range | 3–120 | 3–61 | 3–120 | | |
HR (beats/min) | 62 (10) | 65 (9) | 56 (11) | 0.92 | 0.85 to 0.99* |
Range | 35–87 | 44–87 | 35–84 | | |
cSNRT (ms) | 437 (78) | 428 (73) | 441 (80) | 0.94 | 0.82 to 1.06 |
Range | 290–560 | 310–520 | 290–550 | | |
ERP at BCL (ms) | 184 (21) | 188 (18) | 180 (22) | 1.04 | 1 to 1.08* |
Range | 126–230 | 142–230 | 126–230 | | |
Abnormal ERP/CL (patients) | 42/73 | 18/47 | 24/26 | 31.5 | 3.7 to 266*** |